[关键词]
[摘要]
目的:探讨芬戈莫德(fingolimod,FTY720)对大鼠角膜新生血管(CNV)的抑制作用。
方法:分别采用MTT法和划痕法观察不同浓度FTY720对人脐静脉内皮细胞(HUVECs)的增生和S1P诱导下的细胞迁移的影响。应用大鼠角膜微囊袋模型,检测FTY720对S1P诱导的CNV的作用。将30只SD大鼠按随机数字表法分成A、B和C组,每组10只,在各组角膜基质层内植入S1P的同时依次植入0,5,20μg FTY720缓释颗粒。术后对CNV生长情况观察,并在12d行组织病理学检查。实验结果采用单因素方差分析。
结果:10 ,102 ,103,104 nmol/L FTY720与HUVECs共孵育72h可抑制细胞增生(P<0.01),10,100nmol/L FTY720作用24h后,可抑制由S1P诱导的细胞迁移,随FTY720浓度增加其抑制细胞增生和迁移的作用均增强,A、B、C组大鼠角膜微囊袋缓释微粒体植入后12d,CNV面积分别为10.05±1.19,6.59±0.95,2.70±0.68mm2(F=145.155,P<0.01),A与B组、B与C组间均有统计学差异(P<0.01)。
结论:FTY720能抑制S1P诱导的角膜新生血管生成。
[Key word]
[Abstract]
AIM: To explore the inhibiting effect of FTY720 on corneal neovascularization(CNV)of rat.
METHODS: MTT assay and cells scratch were adopted to observe hyperplasia of human umbilical vein endothelial cells(HUVECs)and cell migration induced by sphingosine-1-phosphate(S1P)after using FTY720 of different concentration. The effect of FTY720 on CNV induced by S1P in a rat corneal micropocket model was detected. 30SD rats were randomly divided into group A, group B and group C with 10 rats per group. S1P and 0μg, 5μg, and 20μg FTY720 controlled-released particles were implanted into the corneal stroma. The growth of CNV and having pathological examination on 12d after the operation was observed. Findings was analyzed by one-way ANOVA.
RESULTS: 10, 102, 103, and 104 nmol/L FTY720 and HUVECs co-incubate 72h could inhibit cell proliferation(P<0.01), 24h after the function of 10,100nmol/L FTY720, it could inhibit S1P-induced cell migration and the ability of restricting cell proliferation and cell migration was enhanced with increasing concentration of FTY720. On 12d, after rat corneal micropocket controlled-release particles was implanted into groups A, B, C, the CNV area were respectively 10.05±1.19, 6.59±0.95, 2.70±0.68mm2(F=145.155, P<0.01), group A and group B was statistically different and this was the same case between group B and group C(P<0.01).
CONCLUSION: FTY720 can inhibit S1P-induced corneal neovascularization.
[中图分类号]
[基金项目]
广东省医学科学技术研究基金(No.B2011269); 广州市医药卫生科技项目(No.201102A213104)